Skip to main navigation Skip to search Skip to main content

Type I interferon restricts type 2 immunopathology through the regulation of group 2 innate lymphoid cells

  • Claudia U. Duerr
  • , Connor D.A. Mccarthy
  • , Barbara C. Mindt
  • , Manuel Rubio
  • , Alexandre P. Meli
  • , Julien Pothlichet
  • , Megan M. Eva
  • , Jean François Gauchat
  • , Salman T. Qureshi
  • , Bruce D. Mazer
  • , Karen L. Mossman
  • , Danielle Malo
  • , Ana M. Gamero
  • , Silvia M. Vidal
  • , Irah L. King
  • , Marika Sarfati
  • , Jörg H. Fritz
  • McGill University
  • University of Montreal
  • Institut Pasteur Paris
  • McMaster University
  • Temple University

Research output: Contribution to journalArticlepeer-review

299 Scopus citations

Abstract

Viral respiratory tract infections are the main causative agents of the onset of infection-induced asthma and asthma exacerbations that remain mechanistically unexplained. Here we found that deficiency in signaling via type I interferon receptor led to deregulated activation of group 2 innate lymphoid cells (ILC2 cells) and infection-associated type 2 immunopathology. Type I interferons directly and negatively regulated mouse and human ILC2 cells in a manner dependent on the transcriptional activator ISGF3 that led to altered cytokine production, cell proliferation and increased cell death. In addition, interferon-γ (IFN-γ) and interleukin 27 (IL-27) altered ILC2 function dependent on the transcription factor STAT1. These results demonstrate that type I and type II interferons, together with IL-27, regulate ILC2 cells to restrict type 2 immunopathology.

Original languageEnglish
Pages (from-to)65-75
Number of pages11
JournalNature Immunology
Volume17
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Dive into the research topics of 'Type I interferon restricts type 2 immunopathology through the regulation of group 2 innate lymphoid cells'. Together they form a unique fingerprint.

Cite this